Relapsed Refractory Mantle Cell Lymphoma clinical trials

Explore recruiting relapsed refractory mantle cell lymphoma clinical trials.

Recruiting relapsed refractory mantle cell lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Refractory Mantle Cell Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)

France, Spain, Germany, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Efficacy of Polatuzumab, Bendamustine and Rituximab in patients with relapsed/refractory mantle cell lymphoma- A single center phase II trial

Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Controlled, Open-label, Multicenter, Inferentially Seamless Phase 2/3 Study of Ibrutinib in Combination With Rituximab Versus Physician’s Choice of Lenalidomide Plus Rituximab or Bortezomib Plus Rituximab in Participants with Relapsed or Refractory Mantle Cell Lymphoma

Czechia, Spain, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A PHASE III, OPEN-LABEL, MULTICENTER RANDOMIZED STUDY EVALUATING GLOFITAMAB AS A SINGLE AGENT VERSUS INVESTIGATOR’S CHOICE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

Italy, France, Sweden, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase I/II trial of Obinutuzumab, ABT-199 (GDC-0199) plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma patients (OAsIs)

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Germany, France, Italy, Poland, Spain, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Relapsed Refractory Mantle Cell Lymphoma trials by city

Relapsed Refractory Mantle Cell Lymphoma in Toronto Relapsed Refractory Mantle Cell Lymphoma in Vancouver Relapsed Refractory Mantle Cell Lymphoma in Montreal Relapsed Refractory Mantle Cell Lymphoma in Calgary Relapsed Refractory Mantle Cell Lymphoma in Edmonton Relapsed Refractory Mantle Cell Lymphoma in Ottawa Relapsed Refractory Mantle Cell Lymphoma in Winnipeg Relapsed Refractory Mantle Cell Lymphoma in Quebec City Relapsed Refractory Mantle Cell Lymphoma in Hamilton Relapsed Refractory Mantle Cell Lymphoma in Kitchener Relapsed Refractory Mantle Cell Lymphoma in London Relapsed Refractory Mantle Cell Lymphoma in Halifax Relapsed Refractory Mantle Cell Lymphoma in New York Relapsed Refractory Mantle Cell Lymphoma in Los Angeles Relapsed Refractory Mantle Cell Lymphoma in Chicago Relapsed Refractory Mantle Cell Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease